Thiamylal

Summary

Thiamylal (CHEMBL440) is an approved small-molecule sedative.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 254.35 Da · C12H18N2O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL440
Name	Thiamylal
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3032285
ChEBI	CHEBI:9536
Molecular formula	C12H18N2O2S
Molecular weight	254.35
InChIKey	XLOMZPUITCYLMJ-UHFFFAOYSA-N

SMILES: CCCC(C)C1(C(=O)NC(=S)NC1=O)CC=C

IUPAC name: 5-pentan-2-yl-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione

ChEBI definition: A member of the class of barbiturates that is 2-thioxodihydropyrimidine-4,6(1H,5H)-dione substituted by a pentan-2-yl and prop-2-en-1-yl group at position 5.

Pharmacological roles (ChEBI): sedative.

Also known as: NSC-120815, Thiamylal, THIAMYLAL

Parent form; salt/anhydrous children: CHEMBL1201065

Patent coverage: 589 distinct patent families (2,056 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,055 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).